Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

Event-Driven

<ul>
<li>The announcement of the inclusion of <a href="https://www.smartkarma.com/entities/uber-technologies-inc" target="_blank" data-smartkarma-citation="entities:430:1" rel="noopener">Uber Technologies (UBER US)</a> in the <a href="https://www.smartkarma.com/entities/s-p-500-index" target="_blank" data-smartkarma-citation="entities:22886:1" rel="noopener">S&amp;P 500 INDEX</a> was a big one last week. There were announcements for some other indices too.</li>
<li>There are many indices in China that will be rebalanced at the close on Friday, the biggest being the <a href="https://www.smartkarma.com/entities/shanghai-shenzhen-csi-300-inde" target="_blank" data-smartkarma-citation="entities:22906:1" rel="noopener">CSI 300</a>, <a href="https://www.smartkarma.com/entities/csi-smallcap-500-index-shang" target="_blank" data-smartkarma-citation="entities:35347:1" rel="noopener">CSI 500</a>, <a href="https://www.smartkarma.com/entities/sse-science-and-technology-innovation-board-50-index" target="_blank" data-smartkarma-citation="entities:29279:1" rel="noopener">STAR50</a>, <a href="https://www.smartkarma.com/entities/shanghai-stock-exchange-sse-50-a-share-index" target="_blank" data-smartkarma-citation="entities:31073:1" rel="noopener">SSE50</a> and <a href="https://www.smartkarma.com/entities/kraneshares-csi-china-internet-etf" target="_blank" data-smartkarma-citation="entities:28208:1" rel="noopener">KWEB US</a>.</li>
<li>Relatively quiet in ETF world with net inflows to China focused ETFs and net outflows for Japan.</li>
</ul>


The announcement of the inclusion of Uber Technologies (UBER US) in the S&amp;P 500 INDEX was a big one last week. There were announcements for some other indices too.
There are many indices in China that will be rebalanced at the close on Friday, the biggest being the CSI 300, CSI 500, STAR50, SSE50 and KWEB US.
Relatively quiet in ETF world with net inflows to China focused ETFs and net outflows for Japan.


Index Rebalance & ETF Flow Recap: KWEB, CSI300/500, STAR50, SSE50, ChiNext, SET50, Chips, Denso, SPX

<ul>
<li>The December rebalance of the <a href="https://www.smartkarma.com/entities/kraneshares-csi-china-internet-etf" target="_blank" data-smartkarma-citation="entities:28208:1" rel="noopener">KraneShares CSI China Internet ETF (KWEB US)</a> will take place at the close of trading on 8 December.</li>
<li>
<a href="https://www.smartkarma.com/entities/fenbi-ltd" target="_blank" data-smartkarma-citation="entities:36640:1" rel="noopener">Fenbi Ltd (2469 HK)</a> and <a href="https://www.smartkarma.com/entities/ysb-inc" target="_blank" data-smartkarma-citation="entities:35982:1" rel="noopener">YSB (9885 HK)</a> will be added to the index and there are no deletions.</li>
<li>There is a big lock-up expiry in <a href="https://www.smartkarma.com/entities/ysb-inc" target="_blank" data-smartkarma-citation="entities:35982:1" rel="noopener">YSB (9885 HK)</a> soon after the index inclusion and this could be an opportunity to access liquidity in the stock.</li>
</ul>


The December rebalance of the KraneShares CSI China Internet ETF (KWEB US) will take place at the close of trading on 8 December.

Fenbi Ltd (2469 HK) and YSB (9885 HK) will be added to the index and there are no deletions.
There is a big lock-up expiry in YSB (9885 HK) soon after the index inclusion and this could be an opportunity to access liquidity in the stock.


KWEB Index Rebalance: Fenbi (2469 HK) & YSB (9885 HK) Added

APAC IPOs & Placements, Aequitas Research

Clarence Chu

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

WuXi XDC Cayman  / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/wuxi-xdc-cayman-inc" target="_blank" data-smartkarma-citation="entities:39917:1" rel="noopener">WuXi XDC Cayman Inc (1877628D HK)</a> is looking to raise &gt;US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are Morgan Stanley, Goldman Sachs, and JP Morgan.</li>
<li>WuXi XDC Cayman (WXDC) is a contract research, development, and manufacturing organization (CRDMO) focused on the global antibody drug conjugates (ADC) and broader bioconjugate market providing integrated and end-to-end services.</li>
<li>As per Frost &amp; Sullivan (F&amp;S), the firm was the second largest CRDMO for ADCs and other bioconjugates globally in terms of FY22 sales.</li>
</ul>



WuXi XDC Cayman Inc (1877628D HK) is looking to raise &gt;US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are Morgan Stanley, Goldman Sachs, and JP Morgan.
WuXi XDC Cayman (WXDC) is a contract research, development, and manufacturing organization (CRDMO) focused on the global antibody drug conjugates (ADC) and broader bioconjugate market providing integrated and end-to-end services.
As per Frost &amp; Sullivan (F&amp;S), the firm was the second largest CRDMO for ADCs and other bioconjugates globally in terms of FY22 sales.


Guangdong Archealth Health Industry Group / Equity Capital Markets

Guangdong Archealth Health Industry Group

<ul>
<li>
<a href="https://www.smartkarma.com/entities/guangdong-archealth-health-industry-group" target="_blank" data-smartkarma-citation="entities:39926:1" rel="noopener">Guangdong Archealth Health Industry Group (GAHI HK)</a> is looking to raise around US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are CICC and ABCI.</li>
<li>Guangdong Archealth Health Industry Group (GAHI) is a digital health management provider.</li>
<li>According to F&amp;S, the firm ranked first in the weight management industry and first in the digital weight management industry in China as per 2022 sales.</li>
</ul>



Guangdong Archealth Health Industry Group (GAHI HK) is looking to raise around US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are CICC and ABCI.
Guangdong Archealth Health Industry Group (GAHI) is a digital health management provider.
According to F&amp;S, the firm ranked first in the weight management industry and first in the digital weight management industry in China as per 2022 sales.


Guangdong Archealth Health Industry Group Tearsheet

Silver Dragon Water Supply Group / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/silver-dragon-water-supply-group" target="_blank" data-smartkarma-citation="entities:39898:1" rel="noopener">Silver Dragon Water Supply Group (2210081D CH)</a> is looking to raise at least US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are HSBC and Huatai International.</li>
<li>Silver Dragon Water Supply Group (SDW) is principally engaged in the supply of tap water, raw water and pipeline direct drinking water in China.</li>
<li>As per Frost &amp; Sullivan (F&amp;S), the firm had the largest water pipeline network in terms of water pipeline length among all water supply companies in China in 2022.</li>
</ul>



Silver Dragon Water Supply Group (2210081D CH) is looking to raise at least US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are HSBC and Huatai International.
Silver Dragon Water Supply Group (SDW) is principally engaged in the supply of tap water, raw water and pipeline direct drinking water in China.
As per Frost &amp; Sullivan (F&amp;S), the firm had the largest water pipeline network in terms of water pipeline length among all water supply companies in China in 2022.


Silver Dragon Water Supply Group Pre-IPO Tearsheet

China

Sihuan Pharmaceutical Holdings Group Ltd. researches and develops cardiocerebral vascular drugs in China. The Company drugs address needs in the areas of anti-infective, metabolism, cardiovascular system, oncology and nervous system.

Consun Pharmaceutical Group Limited is a pharmaceutical company engaged in the research, manufacturing and sale of modern Chinese medicines and medical contrast medium in the People's Republic of China.

Hunan Er-kang Pharmaceutical Company Limited develops, produces and sells pharmaceutical products. The Company's main product include pharmaceutical excipients and antibiotic products.

Yabao Pharmaceutical Group Co., Ltd. manufactures and markets pharmaceutical preparations and chemical synthetic pharmaceuticals.  The Company's products include injections, tablets, capsules, healthcare products, medical packaging materials, and other related products.

Guizhou Bailing Group Pharmaceutical Co, Ltd. is a pharmaceutical company.  The Company's products include tablets, capsules, syrup, soft capsules, granules, pills, and powder.

Gz Bailing Group Pharm Co., Ltd. (002424 CH)

Zhuzhou Qianjin Pharmaceutical Co., Ltd. develops and manufactures pharmaceutical products. The Company's products include Chinese traditional medicines and healthcare products.

Zhuzhou Qianjin Pharmaceutical Co., (600479 CH)

Zhejiang International Group Co., Ltd. mainly manufactures pharmaceutical products, including medicines, healthcare products, medical instruments, and pharmaceutical raw materials.  The Company also manufactures textile products, develops real estate, and provides technical services.

Harbin Gloria Pharmaceuticals Co., Ltd. develops, manufactures and sells pharmaceuticals.  The Company's products are small water needle, freeze-dried powder injection, capsules, tablets, suppositories, powder for injection points installation and oncology medicines etc.

Harbin Gloria Pharmaceuticals Co, Ltd. (002437 CH)

Nantong Jinghua Pharmaceutical Ltd. Co. manufactures and sells Chinese and Western medicine, in the form of tablets, capsules, pills, granules, powder, syrup and mixture.  The Company also produces Chinese healthy food products.

Fuan Pharmaceutical Group Co., Ltd. develops, produces and sells Monocyclic -lactams, penicillins and cephalosporins bulk drugs and formulations. The Company's main products are aztreonam bulk drugs and formulations, ticarcillin sodium, sulbenicillin disodium bulk drugs and formulations, cefathiamidine and ceftizoxime sodium formulations.

TORII PHARMACEUTICAL CO., LTD. produces and sells pharmaceuticals.  The Company promotes medical products of its parent company, Japan Tobacco. Torii Pharmaceutical operates building maintenance and management business as well as shipping business.

ZERIA PHARMACEUTICAL CO., LTD. develops, manufactures, and markets a wide range of pharmaceutical products including prescription and over-the-counter drugs, health food products, and medical tools and appliances.  The Company also manufactures and wholesales cosmetics, soft drink, agrochemicals, and feed stuffs.

PT Tempo Scan Pacific Tbk manufactures and distributes pharmaceutical , health care and cosmetic products. The Company offers a variety of products including prescription drugs, specialty care products, and home care consumer products.

Daewoong Co., Ltd. is a investment holding company which operates biotechnology, marketing system, and healthcare entities.  The Company also invests and develops over-the-counter drugs (OTC).

TTY Biopharm Co., Ltd. manufactures and markets various kinds of medicines. The company's products encompass a variety of therapeutic segments, including cardiology, gastroenterology, orthopedics and cancer.

KYORIN Holdings, Inc. is a holding company who manages Kyorin Group including Kyorin Pharmaceutical.  The Group manufactures and distributes prescription medicine and quasi-drugs, and diagnostic drugs.  Kyorin also manufactures and markets medical tools and equipment, health foods, and cosmetics as well as developing  medical products with other pharmaceutical companies.

Shilpa Medicare Ltd. produces and exports active pharmaceutical ingredients, fine chemicals, intermediates, herbal products, and specialty chemical products.

Aarti Drugs Limited is a pharmaceutical company which manufactures bulk drugs and specialty chemicals. The Company's products include vitamins and sedatives, as well as anti-inflammatory, anti-asthma, anti-arthritis, anti-fungal,  anti-diabetic, anti-osteoporosis, anti-cholinergic and anti-depressant drugs.  The company sells its products in India and elsewhere throughout the world.

ScinoPharm Taiwan Ltd. offers process research and development and the production of active pharmaceutical ingredients. The Company provides services to pharmaceutical industries globally.

JW Pharmaceutical Corp manufactures prescription and over-the counter drugs. The Company produces transfusion fluids, antibiotics, anesthetics, and respiratory and circulatory medications.

YSB Inc. operates as a digital pharmaceutical platform outside of hospitals in China.. The Company provides outside of hospital pharmaceutical circulation services. YSB mainly offers services to pharmaceutical companies, distributors, vendors, pharmacies, primary healthcare institutions, and others.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

YSB (9885 HK)

Index Rebalance & ETF Flow Recap: KWEB, CSI300/500, STAR50, SSE50, ChiNext, SET50, Chips, Denso, SPX

This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...

Brian Freitas

KWEB Index Rebalance: Fenbi (2469 HK) & YSB (9885 HK) Added

Fenbi and YSB will be bought by the KWEB ETF at the close on 8 December. Fenbi also has some passive inflows at month end. YSB has a big lock up...

Brian Freitas

WuXi XDC Cayman Pre-IPO Tearsheet

WuXi XDC Cayman Inc (1877628D HK) is looking to raise >US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are Morgan Stanley,...

Clarence Chu

Guangdong Archealth Health Industry Group Tearsheet

Guangdong Archealth Health Industry Group (GAHI HK) is looking to raise around US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal...

Clarence Chu

Silver Dragon Water Supply Group Pre-IPO Tearsheet

Silver Dragon Water Supply Group (2210081D CH) is looking to raise at least US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are...

Clarence Chu

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)